drugset / Trial / NCT04629131
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TNM002 in Healthy Adults
Phase 1
Completed
32 enrolled
Zhuhai Trinomab Pharmaceutical Co., Ltd.
TIGERMED AUSTRALIA PTY LIMITED · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics properties of TNM002 following a single intramuscular dose in healthy adult subjects.
Timeline
- Start
- 2020-11-25
- Primary completion
- 2021-08-13
- Completion
- 2021-08-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SILTARTOXATUG | Monoclonal antibody | 10 ug/kg | Intramuscular |
| Subject | SILTARTOXATUG | Monoclonal antibody | 35 ug/kg | Intramuscular |
| Subject | SILTARTOXATUG | Monoclonal antibody | 100 ug/kg | Intramuscular |
| Subject | SILTARTOXATUG | Monoclonal antibody | 250 ug/kg | Intramuscular |
Indications
No indication recorded.